Close Menu

Luminex

The firm is selling stock and warrants to purchase stock to raise money for general corporate purposes and working capital. 

The molecular diagnostics company posted record revenues to meet Wall Street's estimate but feel short of estimates on the bottom line.

The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.

Bio-Techne is the second firm to sign an instrument distribution deal with Luminex in recent weeks and will continue to develop assays for the Luminex platform.

The panel is designed to simultaneously detect 21 respiratory pathogens including several atypical bacteria in a single closed-tube system.

As part of the deal, Affymetrix will sell Luminex's Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified geographies.

The firm plans to officially launch and introduce the PCR-based platform and herpes assay over the next several weeks.

Previously for research use only, the Respiratory Pathogen Test for the Verigene System is Nanosphere's fifth infectious disease test to receive FDA clearance.

The Northbrook, Illinois-based molecular diagnostics firm said that sales for its blood culture tests in the quarter increased 87 percent year over year.

The firm saw a profitable quarter driven by increases in assay sales and royalty revenues, despite a $7.1 million legal settlement with Enzo Life Sciences.

Pages

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.